BR112016024895A2 - fator secretório de proteína com alta eficácia secretória e um vetor de expressão compreendendo o mesmo - Google Patents

fator secretório de proteína com alta eficácia secretória e um vetor de expressão compreendendo o mesmo

Info

Publication number
BR112016024895A2
BR112016024895A2 BR112016024895A BR112016024895A BR112016024895A2 BR 112016024895 A2 BR112016024895 A2 BR 112016024895A2 BR 112016024895 A BR112016024895 A BR 112016024895A BR 112016024895 A BR112016024895 A BR 112016024895A BR 112016024895 A2 BR112016024895 A2 BR 112016024895A2
Authority
BR
Brazil
Prior art keywords
secretory
same
expression vector
efficacy
protein factor
Prior art date
Application number
BR112016024895A
Other languages
English (en)
Inventor
Jung Saem
Hae KIM Seung
Chul Kim Yeon
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of BR112016024895A2 publication Critical patent/BR112016024895A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção se refere a um fator de secreção de proteína, um vetor incluindo uma sequência de ácidos nucleicos que codifica o fator de secreção de proteína e uma célula transformada na qual o vetor é introduzido. a invenção tam-bém se refere a um método para produzir uma proteína alvo usando a célula trans-formada incluindo o vetor.
BR112016024895A 2014-04-30 2015-04-30 fator secretório de proteína com alta eficácia secretória e um vetor de expressão compreendendo o mesmo BR112016024895A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140052752A KR102092225B1 (ko) 2014-04-30 2014-04-30 고효율 분비능을 가지는 단백질 분비 인자 및 이를 포함하는 발현 벡터
PCT/KR2015/004389 WO2015167278A1 (en) 2014-04-30 2015-04-30 A protein secretory factor with high secretory efficiency and an expression vector comprising the same

Publications (1)

Publication Number Publication Date
BR112016024895A2 true BR112016024895A2 (pt) 2017-10-24

Family

ID=54358915

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016024895A BR112016024895A2 (pt) 2014-04-30 2015-04-30 fator secretório de proteína com alta eficácia secretória e um vetor de expressão compreendendo o mesmo

Country Status (10)

Country Link
US (3) US10407475B2 (pt)
EP (1) EP3137493B1 (pt)
JP (2) JP6471175B2 (pt)
KR (1) KR102092225B1 (pt)
CN (1) CN106255700B (pt)
AR (1) AR100255A1 (pt)
BR (1) BR112016024895A2 (pt)
MX (2) MX2016013849A (pt)
TW (1) TWI708780B (pt)
WO (1) WO2015167278A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787671B2 (en) 2017-10-27 2020-09-29 Pfenex Inc. Method for production of recombinant Erwinia asparaginase
CA3077393A1 (en) * 2017-10-27 2019-05-02 Pfenex Inc. Bacterial leader sequences for periplasmic protein expression
CN111278979B (zh) 2017-10-27 2024-05-31 佩利肯科技控股公司 重组大肠杆菌天冬酰胺酶的生产方法
CN112654637A (zh) 2018-09-05 2021-04-13 株式会社Lg化学 包含可被o-糖基化的多肽区的融合多肽
CA3123078A1 (en) 2018-12-13 2020-06-18 Huya Bioscience International, Llc Sulcardine administration for treatment of acute atrial fibrillation
JP7253771B2 (ja) * 2019-01-18 2023-04-07 株式会社大一商会 遊技機
JP7253773B2 (ja) * 2019-01-18 2023-04-07 株式会社大一商会 遊技機
JP2022530216A (ja) 2019-04-23 2022-06-28 エルジー・ケム・リミテッド 免疫グロブリンのＦｃ領域およびＧＤＦ１５を含む融合ポリペプチド
WO2021112540A1 (ko) 2019-12-02 2021-06-10 주식회사 엘지화학 Cho 세포 유래 단백질 분비 인자 및 이를 포함하는 발현 벡터
KR20220138352A (ko) 2021-04-05 2022-10-12 주식회사 엘지화학 코로나바이러스 백신 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022847A (en) * 1997-03-19 2000-02-08 Zymogenetics, Inc. Secreted salivary zsig32 polypeptides
AU764441B2 (en) * 1998-02-09 2003-08-21 Genset S.A. cDNAs encoding secreted proteins
US6365369B1 (en) 1998-04-01 2002-04-02 Human Genome Sciences, Inc. Prostate specific secreted protein
US7339033B2 (en) * 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
EP1666493A1 (en) * 2000-06-02 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids ancoding the same
KR20030062854A (ko) 2002-01-21 2003-07-28 주식회사 엘지생명과학 분비형 벡터를 이용한 효모에서의 재조합 단백질의 제조방법
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2004094589A2 (en) 2003-04-18 2004-11-04 Incyte Corporation Secreted proteins
KR20070009269A (ko) * 2005-07-15 2007-01-18 한국생명공학연구원 재조합단백질 생산용 단백질융합인자 라이브러리 및이로부터 획득된 단백질융합인자
JP2007209328A (ja) * 2006-01-13 2007-08-23 Galpharma Co Ltd ガレクチン−９利用遺伝子治療剤
KR100954322B1 (ko) * 2006-06-14 2010-04-21 주식회사 엘지생명과학 췌장암과 관련된 신규한 ｌｂｆｌ313 유전자
CN1903876B (zh) 2006-07-10 2010-09-01 郑鸿 一种多肽、编码它的核酸分子及用途
JP5812418B2 (ja) * 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
KR101868139B1 (ko) 2010-11-30 2018-06-15 주식회사 엘지화학 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터
US20140010861A1 (en) * 2012-04-02 2014-01-09 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
CN104854133B (zh) 2012-10-12 2018-10-30 新加坡科技研究局 用于制备重组抗体治疗剂的最佳重链和轻链信号肽

Also Published As

Publication number Publication date
CN106255700B (zh) 2021-06-18
US20200255485A1 (en) 2020-08-13
EP3137493A4 (en) 2017-11-15
WO2015167278A1 (en) 2015-11-05
JP6471175B2 (ja) 2019-02-13
EP3137493A1 (en) 2017-03-08
US20230212236A1 (en) 2023-07-06
KR20150125402A (ko) 2015-11-09
JP2019006823A (ja) 2019-01-17
MX2016013849A (es) 2017-02-02
EP3137493B1 (en) 2019-09-04
MX2020003508A (es) 2020-07-22
US10407475B2 (en) 2019-09-10
US20170044224A1 (en) 2017-02-16
KR102092225B1 (ko) 2020-03-23
TW201625665A (zh) 2016-07-16
JP2017513511A (ja) 2017-06-01
AR100255A1 (es) 2016-09-21
TWI708780B (zh) 2020-11-01
CN106255700A (zh) 2016-12-21

Similar Documents

Publication Publication Date Title
BR112016024895A2 (pt) fator secretório de proteína com alta eficácia secretória e um vetor de expressão compreendendo o mesmo
CL2020003409A1 (es) Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154)
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
EP4324473A3 (en) Multiparametric nucleic acid optimization
MX2020003995A (es) Nuevas moleculas de acido nucleico artificiales.
MX2023011785A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
BR112017023374A2 (pt) formulação de anticorpo anti-cgrp
BR112017025564B8 (pt) Anticorpos anti-ctla-4 e métodos de uso dos mesmos
MX2017003847A (es) Proteinas biespecificas activables por proteasas.
AR105634A1 (es) Anticuerpos que se unen a il 8 y sus usos
BR112018002150A2 (pt) proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
BR112018010429A2 (pt) ácidos nucleicos que se direcionam a ácidos nucleicos engenheirados
EP3201757A4 (en) Identifying temporal demand for autocomplete search results
EP3354058A4 (en) METHOD FOR AUTONOMOUS IMPLEMENTATION OF A USER DEVICE FOR ACTIONS RELATED TO A MEASUREMENT FOR IMPLIED TRIGGERS
IL251571B (en) Variable proteins comprising the cry1da1 amino acid sequence are activated by lepidopteran
UY36287A (es) COMPUESTO DE OBJETIVO A IL-23A y TNF-ALFA Y USO DEL MISMO
CL2020001137A1 (es) Anticuerpos anti-apoc3 y métodos de uso de estos.
BR112018012851A2 (pt) cepas de expressão de proteína melhoradas
BR112017009152A2 (pt) métodos de produção de proteínas de duas cadeias em bactérias
BR112017002139A2 (pt) ?método para preparar um composto?
CL2017001633A1 (es) Método de manufactura de proteína.
IT201700026465A1 (it) Supplementi per colture cellulari
EP3380844A4 (en) PROCESS FOR CHECKING THE PRIMARY STRUCTURE OF PROTEIN

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: LG CHEM, LTD. (KR)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024010970-0 PROTOCOLO 870240046199 EM 31/05/2024 15:14.